je.st
news
Tag: announce
AkzoNobel and Evonik Announce Production Joint Venture for Chlorine/Potassium Hydroxide Solution
2015-06-16 07:00:00| Coatings World Breaking News
Tags: production
solution
joint
venture
Optical Cable (OCC) Set to Announce Earnings on Friday
2015-06-11 19:04:27| Industrial Machines - Topix.net
Optical Cable will release its Q215 earnings data on Friday, June 12th. Persons that wish to listen to the company's earnings conference call can do so using this link .
Tags: set
friday
cable
optical
Brokerages Anticipate Littelfuse to Announce $1.26 EPS
2015-06-11 17:45:41| Electronics - Topix.net
Shares of Littelfuse have earned a consensus broker rating score of 1.80 from the five analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.
Tags: announce
eps
anticipate
brokerages
ARIAD and Paladin Announce Commercial Distribution Agreement for...
2015-06-10 15:06:27| Agriculture - Topix.net
CAMBRIDGE, Mass., & MONTREAL-- -- ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.
Tags: for
agreement
commercial
distribution
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
2015-06-10 14:46:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & SEOUL, South Korea Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel (etanercept), and SB2, an investigational biosimilar of Remicade (infliximab), met their primary endpoints, demonstrating equivalence to the originator medicine in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
phase
Sites : [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] next »